Tarsus Pharmaceuticals (TARS) Revenue (2021 - 2026)
Tarsus Pharmaceuticals (TARS) posted quarterly Revenue of $162.1 million for Q1 2026, up 106.87% year-over-year from $78.3 million in Q1 2025, and up 6.85% quarter-over-quarter from $151.7 million in Q4 2025.
Tarsus Pharmaceuticals (TARS) Revenue (2021 - 2026) Analysis & Trends
Tarsus Pharmaceuticals' Revenue history runs 6 years deep, the most recent figure standing at $162.1 million for Q1 2026.
- In Q1 2026, Revenue rose 106.87% year-over-year to $162.1 million; the TTM figure through Mar 2026 stood at $535.1 million (up 128.99% YoY), while the FY2025 annual figure was $451.4 million, up 146.71% from the prior year.
- Revenue for Q1 2026 stood at $162.1 million, up from $151.7 million in the prior quarter.
- The five-year high for Revenue was $162.1 million in Q1 2026, with the low at $539000.0 in Q1 2022.
- The 5-year median for Revenue is $40.8 million (2024), against an average of $56.0 million.
- Peak annual rise in Revenue reached 2858.58% in 2022, while the deepest fall reached 98.39% in 2022.
- Tarsus Pharmaceuticals' Revenue stood at $10.0 million in 2022, then soared by 30.76% to $13.1 million in 2023, then soared by 407.86% to $66.4 million in 2024, then jumped by 128.39% to $151.7 million in 2025, then climbed by 6.85% to $162.1 million in 2026.
- Business Quant data shows TARS's Revenue at $162.1 million in Q1 2026, $151.7 million in Q4 2025, and $118.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Tarsus Pharmaceuticals | 2.99 Bn | 2.54 Bn | 161.80 Mn | 173.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 173.91 Mn |
| Mar 31, 2026 | 162.05 Mn |
| Dec 31, 2025 | 151.67 Mn |
| Sep 30, 2025 | 118.70 Mn |
| Jun 30, 2025 | 102.66 Mn |
| Mar 31, 2025 | 78.34 Mn |
| Dec 31, 2024 | 66.41 Mn |
| Sep 30, 2024 | 48.12 Mn |
| Jun 30, 2024 | 40.81 Mn |
| Mar 31, 2024 | 27.61 Mn |
| Dec 31, 2023 | 13.08 Mn |
| Sep 30, 2023 | 1.87 Mn |
| Mar 31, 2023 | 2.50 Mn |
| Dec 31, 2022 | 10.00 Mn |
| Jun 30, 2022 | 15.28 Mn |
| Mar 31, 2022 | 539,000.00 |
| Dec 31, 2021 | 338,000.00 |
| Sep 30, 2021 | 1.24 Mn |
| Jun 30, 2021 | 22.02 Mn |
| Mar 31, 2021 | 33.43 Mn |